IDS, Biosignatures Set License Agreement | GenomeWeb

NEW YORK (GenomeWeb News) – Immunodiagnostic Systems has licensed the right to use new biomarkers developed by Biosignatures for use in immunoassay diagnostic test kits for kidney diseases, IDS said today.

The agreement covers the proteomics-based biomarker technology developed by Biosignatures, a Newcastle, UK-based company that spun out from Nonlinear Dynamics. The initial focus of the license agreement will cover kidney diseases and related conditions and will use the IDS iSYS platform, IDS said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.